OBX (Obsidian Therapeutics) EV-to-EBITDA: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OBX Obsidian Therapeutics Inc OBX
8 GF Score
Price $27.50
View Full Analysis

What is Obsidian Therapeutics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Obsidian Therapeutics's enterprise value is $0.00 Mil. Obsidian Therapeutics does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Obsidian Therapeutics's EV-to-EBITDA at this moment.

The historical rank and industry rank for Obsidian Therapeutics's EV-to-EBITDA or its related term are showing as below:

OBX's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 12.99
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2026-08-08), Obsidian Therapeutics's stock price is $27.50. Obsidian Therapeutics does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Obsidian Therapeutics's PE Ratio (TTM) at this moment.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).

Obsidian Therapeutics  (NAS:OBX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Obsidian Therapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=27.50/
=

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

Obsidian Therapeutics EV-to-EBITDA Related Terms

Obsidian Therapeutics EV-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Obsidian Therapeutics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Obsidian Therapeutics EV-to-EBITDA Chart

Obsidian Therapeutics Annual Data
Trend Dec24 Dec25
EV-to-EBITDA
0.00 0.00

Obsidian Therapeutics Semi-Annual Data
Dec24 Dec25
EV-to-EBITDA 0.00 0.00

OBX vs : EV-to-EBITDA Comparison

For the Biotechnology subindustry, Obsidian Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Obsidian Therapeutics EV-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Obsidian Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Obsidian Therapeutics's EV-to-EBITDA falls into.


OBX
8GF Score
Obsidian Therapeutics Inc OBX
EV-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Obsidian Therapeutics EV-to-EBITDA Calculation

Obsidian Therapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=0.000/
=

Obsidian Therapeutics Business Description

Comparable Companies
Address 1030 Massachusetts Avenue, Suite 400, Cambridge, MA, USA, 02138
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.
8GF Score

Get the complete analysis for OBX

EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.50
Price